Author

L. Levillayer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:non-human primate· 1

Frequent Co-Authors

E. Simon-Loriere· 3 shared M. Prot· 3 shared F. Donati· 2 shared G. Jouvion· 2 shared J. Jaubert· 2 shared L. Conquet· 2 shared M. Albert· 2 shared S. van der Werf· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

E. Simon-Loriere

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A mouse-adapted SARS-CoV-2 strain replicating in standard laboratory mice.

X. Montagutelli, M. Prot, G. Jouvion, L. Levillayer, L. Conquet, E. Reyes-Gomez, F. Donati, M. Albert, S. van der Werf, J. Jaubert, E. Simon-Loriere

This study develops a mouse-adapted SARS-CoV-2 strain that replicates efficiently in standard mice and causes mild to moderate lung disease.

bioRxiv · Jul 10, 2021 · PreprintMicrobiology

Variants with the N501Y mutation extend SARS-CoV-2 host range to mice, with contact transmission

X. Montagutelli, M. Prot, L. Levillayer, E. Baquero Salazar, G. Jouvion, L. Conquet, M. Beretta, F. Donati, M. Albert, F. Gambaro, S. Behillil, V. Enouf, D. Rousset, J. Jaubert, S. van der Werf, , E. Simon-Loriere

The paper shows that SARS-CoV-2 variants with the N501Y mutation can infect and transmit to mice, suggesting potential for rodent reservoirs.

bioRxiv · Mar 18, 2021 · PreprintMicrobiology

Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine

M. Plaze, D. Attali, M. Prot, A.-C. Petit, M. Blatzer, F. Vinckier, L. Levillayer, F. Perin-Dureau, A. Cachia, G. Friedlander, F. Chretien, E. Simon-Loriere, R. Gaillard

This study tests chlorpromazine's antiviral effect on SARS-CoV-2 in human and monkey cells, finding an IC50 of ~10M and suggesting its potential repurposing for COVID-19 treatment.

bioRxiv · May 5, 2020Microbiology